Indication
Relapsed/Refractory Leukemias
1 clinical trial
3 products
Clinical trial
AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination With Chemotherapy in Patients With Relapsed/Refractory Leukemias Harboring Alterations in KMT2A/MLL, Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) GenesStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
RevumenibProduct
Chemotherapy Regimen 1Product
Chemotherapy Regimen 2